MXPA06013388A - Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. - Google Patents
Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.Info
- Publication number
- MXPA06013388A MXPA06013388A MXPA06013388A MXPA06013388A MXPA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A MX PA06013388 A MXPA06013388 A MX PA06013388A
- Authority
- MX
- Mexico
- Prior art keywords
- lentiviral vector
- vaccine
- expression
- applications
- recombinant lentiviral
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 241000710781 Flaviviridae Species 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 208000004576 Flaviviridae Infections Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405366A FR2870126B1 (fr) | 2004-05-17 | 2004-05-17 | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| PCT/IB2005/001753 WO2005111221A1 (en) | 2004-05-17 | 2005-05-16 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06013388A true MXPA06013388A (es) | 2007-06-19 |
Family
ID=34945000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06013388A MXPA06013388A (es) | 2004-05-17 | 2005-05-16 | Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20090214589A1 (enExample) |
| EP (2) | EP2371966B1 (enExample) |
| JP (1) | JP2008508863A (enExample) |
| CN (1) | CN1981043B (enExample) |
| BR (1) | BRPI0510016B8 (enExample) |
| CA (1) | CA2564934C (enExample) |
| FR (1) | FR2870126B1 (enExample) |
| MX (1) | MXPA06013388A (enExample) |
| WO (1) | WO2005111221A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001027304A2 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| FR2870126B1 (fr) * | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US8222029B2 (en) * | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| CA2508266A1 (fr) | 2005-06-20 | 2006-12-20 | Institut Pasteur | Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae |
| EP1939214B1 (en) | 2006-12-22 | 2013-07-10 | Institut Pasteur | Cells and methodology to generate non-segmented negative-strand RNA viruses |
| GB0701253D0 (en) | 2007-01-23 | 2007-02-28 | Diagnostics For The Real World | Nucleic acid amplification and testing |
| CA2721657A1 (en) * | 2008-04-22 | 2009-10-29 | Cytos Biotechnology Ag | Vaccine compositions for the treatment of dengue fever and uses thereof |
| EP2666477A1 (en) | 2012-05-23 | 2013-11-27 | Theravectys | Lentiviral vectors containing an MHC class I promoter |
| WO2012021741A2 (en) * | 2010-08-12 | 2012-02-16 | Clontech Laboratories, Inc. | Lateral flow assays for non-diagnostic analytes |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| SG11201803546WA (en) | 2015-11-09 | 2018-05-30 | Immune Design Corp | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| EP3184119A1 (en) | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| SG11202004234SA (en) | 2017-11-09 | 2020-06-29 | Pasteur Institut | A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1878797B1 (en) * | 1992-07-16 | 2010-04-28 | Advanced Life Science Institute, Inc | Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same |
| US5883081A (en) * | 1995-07-26 | 1999-03-16 | The Regents Of The University Of California | Isolation of novel HIV-2 proviruses |
| US5888767A (en) * | 1996-11-27 | 1999-03-30 | The Johns Hopkins University School Of Medicine | Method of using a conditionally replicating viral vector to express a gene |
| GB2325003B (en) | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| ATE528405T1 (de) | 1997-12-22 | 2011-10-15 | Oxford Biomedica Ltd | Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren |
| CA2318575A1 (en) * | 1998-01-16 | 1999-07-22 | Chiron Corporation | Feline immunodeficiency virus gene therapy vectors |
| FR2777909B1 (fr) * | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| ES2281179T3 (es) | 1998-06-09 | 2007-09-16 | Andrea D. Branch | Nuevos peptidos del virus de la hepatitis c y usos de los mismos. |
| US7052830B1 (en) * | 1998-06-09 | 2006-05-30 | Branch Andrea D | Hepatitis C virus peptides and uses thereof |
| FR2794865B1 (fr) * | 1999-06-09 | 2003-04-18 | Pasteur Institut | Methode de detection precoce des flavivirus et ses applications |
| EP2169073B1 (en) | 1999-10-11 | 2013-11-13 | Institut Pasteur | Vector for the preparation of immunotherapeutical compositions |
| WO2001027304A2 (en) * | 1999-10-12 | 2001-04-19 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| EP1092780A1 (en) | 1999-10-13 | 2001-04-18 | Boehringer Ingelheim International GmbH | Recombiant, replication defective CELO virus and CELO virus DNA |
| CA2443290C (fr) | 2001-04-04 | 2011-11-08 | Institut Pasteur | Souche neurovirulente du virus west-nile et ses applications |
| US20040037848A1 (en) * | 2001-04-06 | 2004-02-26 | Audonnet Jean-Christophe Francis | Recombinant vaccine against West Nile Virus |
| AU2002365244B2 (en) | 2001-07-27 | 2007-12-06 | Zoetis Services Llc | West nile vaccine |
| CA2472468C (en) | 2002-01-10 | 2015-11-24 | Alexander G. Pletnev | Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| EP1572941A4 (en) * | 2002-02-26 | 2009-03-18 | Maxygen Inc | NEW FLAVIVIRUS ANTIGENES |
| US20030194392A1 (en) * | 2002-04-10 | 2003-10-16 | Pierre Charneau | Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
| DE10249594A1 (de) * | 2002-10-24 | 2004-05-13 | Jassoy, Christian, Dr. | Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV) |
| CA2456873A1 (en) * | 2003-02-26 | 2004-08-26 | Centre National De La Recherche Scientifique (C.N.R.S.) | West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications |
| CA2432738A1 (en) * | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| FR2870126B1 (fr) * | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| US8222029B2 (en) * | 2005-05-16 | 2012-07-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
-
2004
- 2004-05-17 FR FR0405366A patent/FR2870126B1/fr not_active Expired - Lifetime
-
2005
- 2005-05-16 US US11/596,675 patent/US20090214589A1/en not_active Abandoned
- 2005-05-16 BR BRPI0510016A patent/BRPI0510016B8/pt active IP Right Grant
- 2005-05-16 MX MXPA06013388A patent/MXPA06013388A/es active IP Right Grant
- 2005-05-16 JP JP2007517517A patent/JP2008508863A/ja active Pending
- 2005-05-16 WO PCT/IB2005/001753 patent/WO2005111221A1/en not_active Ceased
- 2005-05-16 CN CN200580015744XA patent/CN1981043B/zh not_active Expired - Lifetime
- 2005-05-16 EP EP11167507.0A patent/EP2371966B1/en not_active Expired - Lifetime
- 2005-05-16 EP EP05748053.5A patent/EP1751291B1/en not_active Expired - Lifetime
- 2005-05-16 CA CA2564934A patent/CA2564934C/en not_active Expired - Lifetime
-
2011
- 2011-01-07 US US12/929,215 patent/US8716013B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP2371966A1 (en) | 2011-10-05 |
| BRPI0510016B8 (pt) | 2021-05-25 |
| CA2564934A1 (en) | 2005-11-24 |
| EP2371966B1 (en) | 2015-11-25 |
| CN1981043B (zh) | 2010-06-09 |
| BRPI0510016A (pt) | 2007-09-18 |
| WO2005111221A1 (en) | 2005-11-24 |
| BRPI0510016B1 (pt) | 2020-03-10 |
| CN1981043A (zh) | 2007-06-13 |
| FR2870126B1 (fr) | 2009-07-17 |
| EP1751291B1 (en) | 2013-07-31 |
| US20090214589A1 (en) | 2009-08-27 |
| JP2008508863A (ja) | 2008-03-27 |
| US8716013B2 (en) | 2014-05-06 |
| FR2870126A1 (fr) | 2005-11-18 |
| US20110206710A1 (en) | 2011-08-25 |
| EP1751291A1 (en) | 2007-02-14 |
| CA2564934C (en) | 2014-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008054540A3 (en) | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| PT1090033E (pt) | Particulas de proteinas de envelope do hcv: utilizacao para vacinacao | |
| SG156652A1 (en) | Yeast-based therapeutic for chronic hepatitis c infection | |
| NZ515936A (en) | Antigenic Neisserial peptides | |
| WO2006041866A3 (en) | Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes | |
| IL171991A0 (en) | Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject | |
| WO2001045639A3 (en) | Methods for protecting against lethal infection with bacillus anthracis | |
| MXPA05005203A (es) | Vacuna contra vhc. | |
| BRPI0510016B8 (pt) | vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina | |
| ATE401400T1 (de) | Antiangiogene peptide zur behandlung oder vorbeugung von endometriose | |
| FR2828405B1 (fr) | Vaccin anti-coronavirus | |
| DE602006014720D1 (de) | Immunstimulatorische kombination zur vorbeugung und behandlung von hepatitis c | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| WO2005056051A3 (en) | Hepatitis b vaccines and compositions | |
| NZ570708A (en) | Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof | |
| EA200702079A1 (ru) | Вакцина | |
| WO2007101948A3 (fr) | Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus | |
| NZ597470A (en) | Therapeutic peptides, polypeptides ans nucleic acid sequences | |
| NZ591738A (en) | Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella | |
| TR200202169T1 (tr) | Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri. | |
| WO2005016247A3 (en) | Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars | |
| ATE313628T1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen | |
| DE602004028512D1 (de) | Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |